Simon Bury joins Selcia as business development director
This article was originally published in Scrip
Simon Bury has joined the Discovery division of CRO Selcia as business development director to lead expansion plans in its drug discovery offering. Mr Bury most recently served as chief commercial officer for Cyprotex Discovery, where he was responsible for the company's global sales and marketing activities.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.